Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes

by Jasmine A. McQuerry, David F. Jenkins, Susan E. Yost, Yuqing Zhang, Daniel Schmolze, W. Evan Johnson, Yuan Yuan, Andrea H. Bild
Published 2019-09-01

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic...

by Yuan Yuan, Peter Lee, Colt Egelston, Weihua Guo, Susan Yost, Jin Sun Lee, David Rose, Christian Avalos, Paul Frankel, Daniel Schmolze, James Waisman
Published 2021-03-01

Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer

by Angela M. Jarrett, David A. Hormuth, Vikram Adhikarla, Prativa Sahoo, Daniel Abler, Lusine Tumyan, Daniel Schmolze, Joanne Mortimer, Russell C. Rockne, Thomas E. Yankeelov
Published 2020-11-01

Raman spectroscopy and artificial intelligence to predict the Bayesian probability of breast cancer

by Ragini Kothari, Veronica Jones, Dominique Mena, Viviana Bermúdez Reyes, Youkang Shon, Jennifer P. Smith, Daniel Schmolze, Philip D. Cha, Lily Lai, Yuman Fong, Michael C. Storrie-Lombardi
Published 2021-03-01

Raman Spectroscopy for Rapid Evaluation of Surgical Margins during Breast Cancer Lumpectomy

by Willie C. Zúñiga, Veronica Jones, Sarah M. Anderson, Alex Echevarria, Nathaniel L. Miller, Connor Stashko, Daniel Schmolze, Philip D. Cha, Ragini Kothari, Yuman Fong, Michael C. Storrie-Lombardi
Published 2019-10-01

Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab

by Yuan Yuan, Ferdynand J. Kos, Ting-Fang He, Hongwei H. Yin, Mengsha Li, Nicola Hardwick, Kathryn Zurcher, Daniel Schmolze, Peter Lee, Raju K. Pillai, Vincent Chung, Don J. Diamond
Published 2017-12-01

Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis.

by Ting-Fang He, Susan E Yost, Paul H Frankel, Andrew Dagis, Yu Cao, Roger Wang, Anthony Rosario, Travis Yiwey Tu, Shawn Solomon, Daniel Schmolze, Joanne Mortimer, Peter Lee, Yuan Yuan
Published 2020-01-01

Mutation and immune profiling of metaplastic breast cancer: Correlation with survival.

by Michelle Afkhami, Daniel Schmolze, Susan E Yost, Paul H Frankel, Andrew Dagis, Idoroenyi U Amanam, Milhan Telatar, Kim Nguyen, Kim Wai Yu, Thehang Luu, Raju Pillai, Patricia A Aoun, Joanne Mortimer, Yuan Yuan
Published 2019-01-01

Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome

by Juliana C. Wortman, Ting-Fang He, Shawn Solomon, Robert Z. Zhang, Anthony Rosario, Roger Wang, Travis Y. Tu, Daniel Schmolze, Yuan Yuan, Susan E. Yost, Xuefei Li, Herbert Levine, Gurinder Atwal, Peter P. Lee, Clare C. Yu
Published 2021-07-01

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

by Jin Sun Lee, Susan E. Yost, Suzette Blanchard, Daniel Schmolze, Hongwei Holly Yin, Raju Pillai, Kim Robinson, Aileen Tang, Norma Martinez, Jana Portnow, Wei Wen, John H. Yim, Heather Ann Brauer, Yuqi Ren, Thehang Luu, Joanne Mortimer, Yuan Yuan
Published 2019-11-01